{"commentary":{"count":82,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":33,"podcast":27,"youtube":21,"x_video":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04230109\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NeoSTAR","nct_id":"NCT04230109","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=neostar-nct04230109. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"NeoSTAR","arms":[{"description":"\\- The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.\n\n* Sacituzumab govitecan via iv, predetermined dosage per protocol, IV, 2 days per each 21-day cycle, for 4 cycles.\n* This can be followed by standard chemotherapy at the discretion of treating physician.","label":"Sacituzumab Govitecan (monotherapy cohort)","type":"EXPERIMENTAL"},{"description":"\\- The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.\n\n* Sacituzumab govitecan via iv, predetermined dosage per protocol, IV, 2 days per each 21-day cycle, for 4 cycles.\n* Pembrolizumab via iv, predetermined dosage per protocol, IV, 1 day per each 21-day cycle, for 4 cycles.\n* This can be followed by standard chemotherapy at the discretion of treating physician.","label":"Sacituzumab Govitecan and Pembrolizumab (combination cohort)","type":"EXPERIMENTAL"}],"collaborators":["Gilead Sciences"],"completion_date":{"date":"2029-10","type":"ESTIMATED"},"conditions":["Invasive Breast Cancer","Triple Negative Breast Cancer","ER-Negative Breast Cancer","PR-Negative Breast Cancer","HER2-negative Breast Cancer"],"enrollment":{"count":239,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Sacituzumab Govitecan","type":"DRUG"},{"name":"Pembrolizumab","type":"DRUG"}],"last_update":"2026-07-17","lead_sponsor":"Massachusetts General Hospital","official_title":"A Phase 2 Study of Response-guided Neoadjuvant Sacituzumab Govitecan (IMMU-132) in Patients With Localized Triple-Negative Breast Cancer (NeoSTAR)","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2028-10","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Pathological complete response(pCR) rate with sacituzumab govitecan","timeFrame":"12 Weeks"}],"references":[{"citation":"Spring LM, Tolaney SM, Fell G, Bossuyt V, Abelman RO, Wu B, Maheswaran S, Trippa L, Comander A, Mulvey T, McLaughlin S, Ryan P, Ryan L, Abraham E, Rosenstock A, Garrido-Castro AC, Lynce F, Moy B, Isakoff SJ, Tung N, Mittendorf EA, Ellisen LW, Bardia A. Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial. Ann Oncol. 2024 Mar;35(3):293-301. doi: 10.1016/j.annonc.2023.11.018. Epub 2023 Dec 12.","pmid":"38092228","type":"DERIVED"}],"start_date":{"date":"2020-07-14","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Sacituzumab Govitecan In TNBC","url":"https://clinicaltrials.gov/study/NCT04230109"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/neostar-nct04230109"}